Monitoring antibody titers to recombinant Core-NS3 fusion polypeptide is useful for evaluating hepatitis C virus infection and responses to interferon-alpha therapy.
10.3346/jkms.1999.14.2.165
- Author:
Young Min PARK
1
;
Byung Hun BYUN
;
Jong Young CHOI
;
Si Hyun BAE
;
Boo Sung KIM
;
Hong Soeb SO
;
Wang Shick RYU
Author Information
1. Department of Internal Medicine, Kangnam St. Mary's Hospital, Seoul, Korea. ympark@cmc.cuk.ac.kr
- Publication Type:Original Article ; Research Support, Non-U.S. Gov't
- Keywords:
Viral fusion proteins;
Hepatitis C-like viruses;
Hepatitis C antibodies
- MeSH:
Adult;
Aged;
Female;
Genotype;
Hepatitis C/immunology*;
Hepatitis C/drug therapy*;
Hepatitis C/diagnosis;
Hepatitis C/blood;
Hepatitis C Antibodies/immunology*;
Hepatitis C Antibodies/blood;
Hepatitis C Antigens/immunology*;
Hepatitis C-Like Viruses/immunology*;
Hepatitis C-Like Viruses/genetics;
Human;
Immunoblotting;
Interferon Alfa-2a/therapeutic use*;
Male;
Middle Age;
RNA, Viral/blood;
Recombinant Fusion Proteins/immunology;
Viral Core Proteins/immunology*;
Viral Nonstructural Proteins/immunology*
- From:Journal of Korean Medical Science
1999;14(2):165-170
- CountryRepublic of Korea
- Language:English
-
Abstract:
To evaluate the clinical feasibility of the antibody titer against a chimeric polypeptide (named Core 518), in which a domain of Core and NS3 of hepatitis C virus (HCV) was fused, ELISA was performed in a total of 76 serum samples. Each serum was serially diluted using two-fold dilution method with distilled water into 10 concentrations. They were all positive for second generation anti-HCV assay (HCV EIA II; Abbott Laboratories). Genotyping RT-PCR, quantitative competitive RT-PCR, and RIBA (Lucky Confirm; LG Biotech) were also assayed. Anti-Core 518 antibody was detected in x 12800 or higher dilutions of sera from 35 of 43 chronic hepatitis C (81.4%) and nine of 16 hepatocellular carcinoma sera (56.3%), one of four cirrhosis (25%), 0 of four acute hepatitis C, and one of nine healthy isolated anti-HCV-positive subjects (p=0.0000). The anti-Core 518 antibody titers were well correlated with the presence of HCV RNA in serum (p=0.002). The anti-Core 518 antibody titers decreased significantly in nine of ten responders to IFN-alpha treatment. Monitoring anti-Core 518 titers may be helpful not only for differentiating the status of HCV infection among patients with various type C viral liver diseases, but also for predicting responses to IFN-alpha treatment.
